Trial Profile
A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; VX 152 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 21 Feb 2018 Status changed from recruiting to completed.
- 18 Jul 2017 Results published in the Vertex Pharmaceuticals media release.
- 08 Jan 2017 According to a Vertex Pharmaceuticals media release, the first data from this trial are expected in the second half of 2017.